1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Sanofi

Sanofi

  • April 2020
  • 53 pages
  • ID: 5780038
  • Format: PDF
  • Pharma Intelligence

Summary

Table of Contents

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Sanofi will see strong pharmaceutical revenue growth over the forecast period, driven by Dupixent.
Key themes – [1] Strong Dupixent growth, across all indications, led Sanofi management to raise long-term product sales expectations, to €10bn [2] Sanofi announced that it would be discontinuing research in diabetes and cardiovascular diseases to optimize RandD productivity; diabetes sales should continue to decline over the forecast period, as the US pricing environment remains challenging [3] Vaccines remain an area of growth for Sanofi.

Model updates (9 March 2020)

Dupixent forecast adjusted higher due to continued growth in atopic dermatitis, plus a rapid ramp-up in sales for asthma and the launch of the product as a treatment for nasal polyps
Kevzara forecast adjusted due to restructuring of Sanofi/Regeneron alliance
Praluent forecast adjusted lower due to restructuring of Sanofi/Regeneron alliance
Efpeglenatide forecast removed due to Sanofi not pursuing launch.

Model updates (7 November 2019)

Dupixent forecast adjusted higher due to robust uptake across all indications and geographies
Aubagio forecast adjusted higher due to continued market share gains among CGRPs
Praluent forecast adjusted lower in the US due to significantly higher rebates
Admelog forecast adjusted higher in the US
Soliqua forecast adjusted lower due to slower-than-anticipated growth internationally.

Model updates (6 August 2019)

Lantus forecast adjusted lower
Dupixent forecast adjusted higher due to continued uptake in atopic dermatitis and asthma
LixiLan forecast adjusted lower due to lower-than-expected sales
Praluent forecast adjusted lower due to German court injunction
Quadracel forecast adjusted lower
Removed sotagliflozin from forecast after Sanofi terminated the collaboration with Lexicon
Avalglucosidase alfa forecast added
Efpeglenatide forecast added
SAR341402 forecast added
Isatuximab forecast added
Olipudase alfa forecast added
Sutimlimab forecast added.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on